A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine



Status:Archived
Conditions:Cancer, Blood Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:April 2007
End Date:April 2012

Use our guide to learn which trials are right for you!

A Phase I Dose Escalation Study of Oral SB939 When Administered Thrice Weekly (Every Other Day) for 3 Weeks in a 4-week Cycle in Patients With Advanced Malignancies


This is an open label, dose escalation study with 3 arms (Arms A, B, and C). Arm A will
assess the safety and tolerability of escalating doses of SB939 in cohorts of patients with
advanced solid tumors. Arm B will assess the safety and tolerability of escalating doses in
cohorts of patients with advanced hematologic malignancies. Arm C will assess the safety and
tolerability of SB939 in combination with standard azacitidine therapy.



We found this trial at
2
sites
Madison, Wisconsin 53706
(608) 263-2400
University of Wisconsin-Madison In achievement and prestige, the University of Wisconsin-Madison has long been recognized...
?
mi
from
Madison, WI
Click here to add this to my saved trials
1400 South Orange Avenue
Orlando, Florida 32806
407-648-3800
M. D. Anderson Cancer Center Welcome to UF Health Cancer Center at Orlando Health. For...
?
mi
from
Orlando, FL
Click here to add this to my saved trials